Danuglipron
Chemical compound
- Investigational
- 2-[[4-[6-[(4-Cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid
- 2230198-02-2
- 134611040
- DN9IUI24GP
- CHEBI:231951
- ChEMBL4518483
- DTXSID601101457
- Interactive image
- C1CO[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)N=C2CN4CCC(CC4)C5=NC(=CC=C5)OCC6=C(C=C(C=C6)C#N)F
InChI
- InChI=1S/C31H30FN5O4/c32-25-14-20(16-33)4-5-23(25)19-41-30-3-1-2-26(35-30)21-8-11-36(12-9-21)18-29-34-27-7-6-22(31(38)39)15-28(27)37(29)17-24-10-13-40-24/h1-7,14-15,21,24H,8-13,17-19H2,(H,38,39)/t24-/m0/s1
- Key:HYBAKUMPISVZQP-DEOSSOPVSA-N
Danuglipron is a small-molecule GLP-1 agonist developed by Pfizer[1] that, in an oral formulation, is under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicate that it reduced weight[2] and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting.[3][4]
See also
- Lotiglipron
- Orforglipron
References
- ^ Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, et al. (June 2022). "A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor". Journal of Medicinal Chemistry. 65 (12): 8208–8226. doi:10.1021/acs.jmedchem.1c01856. PMC 9234956. PMID 35647711.
- ^ Medical Weight Loss
- ^ Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, Birnbaum MJ (May 2023). "Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial". JAMA Network Open. 6 (5): e2314493. doi:10.1001/jamanetworkopen.2023.14493. PMC 10203889. PMID 37213102.
- ^ Constantino, Annika Kim (2023-12-02). "Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops". CNBC. Retrieved 2023-12-03.
- v
- t
- e
|
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e